{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:56:26Z","timestamp":1793134586859,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T00:00:00Z","timestamp":1478044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/nrclinonc.2016.168","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T09:01:06Z","timestamp":1478077266000},"page":"203-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":413,"title":["PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas"],"prefix":"10.1038","volume":"14","author":[{"given":"Aaron","family":"Goodman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,2]]},"reference":[{"key":"BFnrclinonc2016168_CR1","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105\u20132105 (1999).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR2","first-page":"S11","volume":"6","author":"MB Atkins","year":"2000","unstructured":"Atkins, M. B., Kunkel, L., Sznol, M. & Rosenberg, S. A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6, S11\u201314 (2000).","journal-title":"Cancer J. Sci. Am."},{"key":"BFnrclinonc2016168_CR3","first-page":"S55","volume":"6","author":"RI Fisher","year":"2000","unstructured":"Fisher, R. I., Rosenberg, S. A. & Fyfe, G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6, S55\u2013S57 (2000).","journal-title":"Cancer J. Sci. Am."},{"key":"BFnrclinonc2016168_CR4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907\u2013913 (1994).","journal-title":"JAMA"},{"key":"BFnrclinonc2016168_CR5","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas, T. L., Bakker, C. Y. & Bluestone, J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183, 2541\u20132550 (1996).","journal-title":"J. Exp. Med."},{"key":"BFnrclinonc2016168_CR6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrclinonc2016168_CR7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2012-10-385591","volume":"121","author":"P Greaves","year":"2013","unstructured":"Greaves, P. & Gribben, J. G. The role of B7 family molecules in hematologic malignancy. Blood 121, 734\u2013744 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrclinonc2016168_CR9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793\u2013800 (2002).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2016168_CR11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2016168_CR14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020\u20131030 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR17","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR18","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"BFnrclinonc2016168_CR20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847\u2013856 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc2016168_CR21","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer, M. G. et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34, 2690\u20132697 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","volume":"38","author":"M Shi","year":"2014","unstructured":"Shi, M. et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am. J. Surg. Pathol. 38, 1715\u20131723 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrclinonc2016168_CR23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy, B. et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127, 869\u2013881 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR24","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR27","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","volume":"27","author":"J Carreras","year":"2009","unstructured":"Carreras, J. et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 27, 1470\u20131476 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","volume":"42","author":"BG Richendollar","year":"2011","unstructured":"Richendollar, B. G., Pohlman, B., Elson, P. & Hsi, E. D. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum. Pathol. 42, 552\u2013557 (2011).","journal-title":"Hum. Pathol."},{"key":"BFnrclinonc2016168_CR29","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn, L. H. et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 23, 5027\u20135033 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235\u2013242 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107, 265\u2013276 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR32","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2014-09-551556","volume":"125","author":"P Johnson","year":"2015","unstructured":"Johnson, P. & McKenzie, H. How I treat advanced classical Hodgkin lymphoma. Blood 125, 1717\u20131723 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","volume":"154","author":"AK Ng","year":"2011","unstructured":"Ng, A. K. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br. J. Haematol. 154, 23\u201331 (2011).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2016168_CR34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2004-12-4689","volume":"106","author":"JC Lavoie","year":"2005","unstructured":"Lavoie, J. C. et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106, 1473\u20131478 (2005).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR35","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183\u20132189 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR36","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen, R. et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128, 1562\u20131566 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR37","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","volume":"119","author":"R Chen","year":"2012","unstructured":"Chen, R. et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119, 6379\u20136381 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","volume":"103","author":"NA Marshall","year":"2004","unstructured":"Marshall, N. A. et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103, 1755\u20131762 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR39","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood-2006-12-064360","volume":"110","author":"JM Chemnitz","year":"2007","unstructured":"Chemnitz, J. M. et al. RNA fingerprints provide direct evidence for the inhibitory role of TGF\u03b2 and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood 110, 3226\u20133233 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR40","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18, 1611\u20131618 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR41","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268\u20133277 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR42","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen, B. J. et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 19, 3462\u20133473 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR43","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","volume":"111","author":"R Yamamoto","year":"2008","unstructured":"Yamamoto, R. et al. PD-1\u2013PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111, 3220\u20133224 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR44","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1349-7006.2009.01302.x","volume":"100","author":"R Yamamoto","year":"2009","unstructured":"Yamamoto, R. et al. B7-H1 expression is regulated by MEK\/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci. 100, 2093\u20132100 (2009).","journal-title":"Cancer Sci."},{"key":"BFnrclinonc2016168_CR45","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","volume":"20","author":"Y Hao","year":"2014","unstructured":"Hao, Y. et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin. Cancer Res. 20, 2674\u20132683 (2014).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/leu.2008.272","volume":"23","author":"T Kozako","year":"2009","unstructured":"Kozako, T. et al. PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients. Leukemia 23, 375\u2013382 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2016168_CR47","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","volume":"32","author":"RH Advani","year":"2014","unstructured":"Advani, R. H. et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J. Clin. Oncol. 32, 912\u2013918 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR48","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","volume":"33","author":"DA Eichenauer","year":"2015","unstructured":"Eichenauer, D. A. et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J. Clin. Oncol. 33, 2857\u20132862 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR49","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","volume":"30","author":"DM Dorfman","year":"2006","unstructured":"Dorfman, D. M., Brown, J. A., Shahsafaei, A. & Freeman, G. J. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 30, 802\u2013810 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrclinonc2016168_CR50","doi-asserted-by":"publisher","unstructured":"Armand, P. et al. PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. J. Clin. Oncol. http:\/\/dx.doi.org\/10.1200\/JCO.2016.67.3467 (2016).","DOI":"10.1200\/JCO.2016.67.3467"},{"issue":"Suppl.","key":"BFnrclinonc2016168_CR51","doi-asserted-by":"crossref","first-page":"abstr. 7555","DOI":"10.1200\/JCO.2016.34.15_suppl.7555","volume":"34","author":"R Chen","year":"2016","unstructured":"Chen, R. et al. Pembrolizumab for relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL): phase 2 KEYNOTE-087 study. J. Clin. Oncol. 34 (Suppl.), abstr. 7555 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2016168_CR52","doi-asserted-by":"crossref","first-page":"abstr. 7535","DOI":"10.1200\/JCO.2016.34.15_suppl.7535","volume":"34","author":"A Younes","year":"2016","unstructured":"Younes, A. et al. Checkmate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) \u2014 a phase 2 study. J. Clin Oncol. 34 (Suppl.), abstr. 7535 (2016).","journal-title":"J. Clin Oncol."},{"key":"BFnrclinonc2016168_CR53","unstructured":"US Food and Drug Administration. Nivolumab (Opdivo) for Hodgkin lymphoma. FDA http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm501412.htm (2016)."},{"key":"BFnrclinonc2016168_CR54","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1200\/JCO.2009.23.6018","volume":"27","author":"A-M Tsimberidou","year":"2009","unstructured":"Tsimberidou, A.-M., Braiteh, F., Stewart, D. J. & Kurzrock, R. Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J. Clin. Oncol. 27, 6243\u20136250 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2016168_CR55","doi-asserted-by":"crossref","first-page":"TPS7573","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7573","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand, P. et al. A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D [abstract]. J. Clin. Oncol. 34 (Suppl.), TPS7573 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR56","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02758717 (2016)."},{"key":"BFnrclinonc2016168_CR57","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02581631 (2016)."},{"key":"BFnrclinonc2016168_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01896999 (2016)."},{"key":"BFnrclinonc2016168_CR59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-05-575092","volume":"125","author":"K Dunleavy","year":"2015","unstructured":"Dunleavy, K. & Wilson, W. H. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood 125, 33\u201339 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR60","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy, K. et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med. 368, 1408\u20131416 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR61","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage, K. J. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871\u20133879 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR62","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","volume":"123","author":"DDW Twa","year":"2014","unstructured":"Twa, D. D. W. et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123, 2062\u20132065 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR63","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-11-683003","volume":"128","author":"LC Chong","year":"2016","unstructured":"Chong, L. C. et al. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. Blood 128, 1206\u20131213 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR64","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3109\/10428194.2014.985673","volume":"56","author":"DDW Twa","year":"2015","unstructured":"Twa, D. D. W. & Steidl, C. Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leuk. Lymphoma 56, 2239\u20132250 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2016168_CR65","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/PAS.0000000000000473","volume":"39","author":"J Yuan","year":"2015","unstructured":"Yuan, J. et al. Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling: Am. J. Surg. Pathol. 39, 1322\u20131330 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrclinonc2016168_CR66","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","volume":"118","author":"C Steidl","year":"2011","unstructured":"Steidl, C. & Gascoyne, R. D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118, 2659\u20132669 (2011).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR67","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/gcc.20420","volume":"46","author":"MA Weniger","year":"2007","unstructured":"Weniger, M. A. et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes. Chromosomes Cancer 46, 406\u2013415 (2007).","journal-title":"Genes. Chromosomes Cancer"},{"key":"BFnrclinonc2016168_CR68","doi-asserted-by":"publisher","unstructured":"Gowrishankar, K. et al. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-\u03baB. PLoS ONE http:\/\/dx.doi.org\/10.1371\/journal.pone.0123410 (2015).","DOI":"10.1371\/journal.pone.0123410"},{"key":"BFnrclinonc2016168_CR69","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin, A. M. et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J. Clin. Oncol. 34, 2698\u20132704 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR70","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02576990 (2016)."},{"key":"BFnrclinonc2016168_CR71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2007-01-041871","volume":"110","author":"JO Armitage","year":"2007","unstructured":"Armitage, J. O. How I treat patients with diffuse large B-cell lymphoma. Blood 110, 29\u201336 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125, 22\u201332 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR73","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert, M. et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 2373\u20132380 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR74","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184\u20134190 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR75","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937\u20131947 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","volume":"8","author":"MA Shipp","year":"2002","unstructured":"Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8, 68\u201374 (2002).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2016168_CR77","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","volume":"17","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky, D. J. et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 17, 4232\u20134244 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","volume":"54","author":"T Menter","year":"2016","unstructured":"Menter, T., Bodmer-Haecki, A., Dirnhofer, S. & Tzankov, A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum. Pathol. 54, 17\u201324 (2016).","journal-title":"Hum. Pathol."},{"key":"BFnrclinonc2016168_CR79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","volume":"126","author":"A Nicolae","year":"2015","unstructured":"Nicolae, A. et al. EBV-positive large B cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 126, 863\u2013872 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR80","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu, J. et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126, 2193\u20132201 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR81","doi-asserted-by":"publisher","unstructured":"Baumjohann, D., Baumjohann, D. & Ansel, K. M. Identification of T follicular helper (Tfh) cells by flow cytometry. Protoc. Exch. http:\/\/dx.doi.org\/10.1038\/protex.2013.060 (2013).","DOI":"10.1038\/protex.2013.060"},{"key":"BFnrclinonc2016168_CR82","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621\u2013663 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrclinonc2016168_CR83","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","volume":"11","author":"KL Good-Jacobson","year":"2010","unstructured":"Good-Jacobson, K. L. et al. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 11, 535\u2013542 (2010).","journal-title":"Nat. Immunol."},{"key":"BFnrclinonc2016168_CR84","doi-asserted-by":"crossref","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","volume":"8","author":"JR Kim","year":"2013","unstructured":"Kim, J. R. et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE 8, e82870 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2016168_CR85","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757\u20131761 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR86","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00428-014-1615-5","volume":"465","author":"MJ Ahearne","year":"2014","unstructured":"Ahearne, M. J. et al. Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. Virchows Arch. 465, 351\u2013358 (2014).","journal-title":"Virchows Arch."},{"key":"BFnrclinonc2016168_CR87","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064\u20135074 (2014).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR88","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","volume":"28","author":"D Rossille","year":"2014","unstructured":"Rossille, D. et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 28, 2367\u20132375 (2014).","journal-title":"Leukemia"},{"key":"BFnrclinonc2016168_CR89","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044\u20133051 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR90","unstructured":"Carroll, J. Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study. FierceBiotech http:\/\/www.fiercebiotech.com\/r-d\/anti-pd-1-well-no-says-medivation-as-a-partial-hold-forces-a-halt-to-pivotal-cancer-study (2016)."},{"key":"BFnrclinonc2016168_CR91","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","volume":"31","author":"P Armand","year":"2013","unstructured":"Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199\u20134206 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR92","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/CCO.0b013e3282c8c90d","volume":"6","author":"MJ Silverberg","year":"2007","unstructured":"Silverberg, M. J. & Abrams, D. I. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr. Opin. Intern. Med. 6, 642\u2013647 (2007).","journal-title":"Curr. Opin. Intern. Med."},{"key":"BFnrclinonc2016168_CR93","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","volume":"119","author":"K Dunleavy","year":"2012","unstructured":"Dunleavy, K. & Wilson, W. H. How I treat HIV-associated lymphoma. Blood 119, 3245\u20133255 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR94","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","volume":"116","author":"M Bower","year":"2010","unstructured":"Bower, M. How I treat HIV-associated multicentric Castleman disease. Blood 116, 4415\u20134421 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR95","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2013.1.382","volume":"2013","author":"RF Little","year":"2013","unstructured":"Little, R. F. & Dunleavy, K. Update on the treatment of HIV-associated hematologic malignancies. Hematology Am. Soc. Hematol. Educ. Program 2013, 382\u2013388 (2013).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"BFnrclinonc2016168_CR96","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/cncr.30112","volume":"122","author":"AJ Olszewski","year":"2016","unstructured":"Olszewski, A. J., Fallah, J. & Castillo, J. J. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base. Cancer 122, 2689\u20132697 (2016).","journal-title":"Cancer"},{"key":"BFnrclinonc2016168_CR97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jnci\/89.4.301","volume":"89","author":"JA Sparano","year":"1997","unstructured":"Sparano, J. A. et al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. J. Natl Cancer Inst. 89, 301\u2013307 (1997).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc2016168_CR98","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdu203","volume":"25","author":"C Chao","year":"2014","unstructured":"Chao, C. et al. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann. Oncol. 25, 1821\u20131829 (2014).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2016168_CR99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrclinonc.2014.31","volume":"11","author":"A Carbone","year":"2014","unstructured":"Carbone, A. et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat. Rev. Clin. Oncol. 11, 223\u2013238 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR100","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687 (2006).","journal-title":"Nature"},{"key":"BFnrclinonc2016168_CR101","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350\u2013354 (2006).","journal-title":"Nature"},{"key":"BFnrclinonc2016168_CR102","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1182\/blood.V96.9.3094","volume":"96","author":"P Shankar","year":"2000","unstructured":"Shankar, P. et al. Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. Blood 96, 3094\u20133101 (2000).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR103","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198\u20131202 (2006).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2016168_CR104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-015-0144-x","volume":"12","author":"V Velu","year":"2015","unstructured":"Velu, V., Shetty, R. D., Larsson, M. & Shankar, E. M. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 12, 14 (2015).","journal-title":"Retrovirology"},{"key":"BFnrclinonc2016168_CR105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nm.4113","volume":"22","author":"R Banga","year":"2016","unstructured":"Banga, R. et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754\u2013761 (2016).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2016168_CR106","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nm.3109","volume":"19","author":"RA Cubas","year":"2013","unstructured":"Cubas, R. A. et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 19, 494\u2013499 (2013).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2016168_CR107","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.3141","volume":"19","author":"S Pillai","year":"2013","unstructured":"Pillai, S. Love the one you're with: the HIV, B cell and TFH cell triangle. Nat. Med. 19, 401\u2013402 (2013).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2016168_CR108","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127","author":"BS Kahl","year":"2016","unstructured":"Kahl, B. S. & Yang, D. T. Follicular lymphoma: evolving therapeutic strategies. Blood 127, 2055\u20132063 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR109","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood.V80.4.879.879","volume":"80","author":"SJ Korsmeyer","year":"1992","unstructured":"Korsmeyer, S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80, 879\u2013886 (1992).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42\u201351 (2011).","journal-title":"Lancet"},{"key":"BFnrclinonc2016168_CR111","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig, T. E. et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 5404\u20135409 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR112","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn, I. W. et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123, 3406\u20133413 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR113","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien, K. et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102, 3521\u20133529 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR114","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1200\/JCO.2005.26.856","volume":"23","author":"D de Jong","year":"2005","unstructured":"de Jong, D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J. Clin. Oncol. 23, 6358\u20136363 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR115","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159\u20132169 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR116","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","volume":"20","author":"JP Smeltzer","year":"2014","unstructured":"Smeltzer, J. P. et al. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin. Cancer Res. 20, 2862\u20132872 (2014).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2016168_CR117","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","volume":"121","author":"JH Myklebust","year":"2013","unstructured":"Myklebust, J. H. et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 121, 1367\u20131376 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR118","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2006","unstructured":"Nakanishi, J. et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56, 1173\u20131182 (2006).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrclinonc2016168_CR119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","volume":"108","author":"C Wu","year":"2006","unstructured":"Wu, C. et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108, 19\u201324 (2006).","journal-title":"Acta Histochem."},{"key":"BFnrclinonc2016168_CR120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","volume":"15","author":"JR Westin","year":"2014","unstructured":"Westin, J. R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69\u201377 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2016168_CR121","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis, T. A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18, 3135\u20133143 (2000).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR122","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2249.2001.01582.x","volume":"125","author":"MA Frassanito","year":"2001","unstructured":"Frassanito, M. A., Cusmai, A. & Dammacco, F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin. Exp. Immunol. 125, 190\u2013197 (2001).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrclinonc2016168_CR123","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","volume":"104","author":"T Hideshima","year":"2004","unstructured":"Hideshima, T., Bergsagel, P. L., Kuehl, W. M. & Anderson, K. C. Advances in biology of multiple myeloma: clinical applications. Blood 104, 607\u2013618 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR124","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","volume":"27","author":"H Tamura","year":"2013","unstructured":"Tamura, H. et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27, 464\u2013472 (2013).","journal-title":"Leukemia"},{"key":"BFnrclinonc2016168_CR125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","volume":"110","author":"J Liu","year":"2007","unstructured":"Liu, J. et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110, 296\u2013304 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR126","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson","year":"2010","unstructured":"Benson, D. M. et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286\u20132294 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR127","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","volume":"17","author":"WHD Hallett","year":"2011","unstructured":"Hallett, W. H. D., Jing, W., Drobyski, W. R. & Johnson, B. D. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol. Blood Marrow Transplant. 17, 1133\u20131145 (2011).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrclinonc2016168_CR128","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293\u201312297 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc2016168_CR129","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","volume":"190","author":"TJ Kearl","year":"2013","unstructured":"Kearl, T. J., Jing, W., Gershan, J. A. & Johnson, B. D. Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J. Immunol. 190, 5620\u20135628 (2013).","journal-title":"J. Immunol."},{"key":"BFnrclinonc2016168_CR130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","volume":"106","author":"AA Jungbluth","year":"2005","unstructured":"Jungbluth, A. A. et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106, 167\u2013174 (2005).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR131","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2005-02-0563","volume":"106","author":"O Goodyear","year":"2005","unstructured":"Goodyear, O. et al. CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106, 4217\u20134224 (2005).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR132","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","volume":"98","author":"E Alyea","year":"2001","unstructured":"Alyea, E. et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98, 934\u2013939 (2001).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR133","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207\u20131219 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR134","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik, J. et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384\u2013394 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","volume":"62","author":"K Luptakova","year":"2013","unstructured":"Luptakova, K. et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol. Immunother. 62, 39\u201349 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnrclinonc2016168_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02431208 (2016)."},{"key":"BFnrclinonc2016168_CR137","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","volume":"114","author":"RA Wilcox","year":"2009","unstructured":"Wilcox, R. A. et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114, 2149\u20132158 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR138","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec, M. et al. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl Acad. Sci. USA 105, 20852\u201320857 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc2016168_CR139","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","volume":"39","author":"L Xerri","year":"2008","unstructured":"Xerri, L. et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia. Hum. Pathol. 39, 1050\u20131058 (2008).","journal-title":"Hum. Pathol."},{"key":"BFnrclinonc2016168_CR140","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3892\/ol.2014.2356","volume":"8","author":"L Han","year":"2014","unstructured":"Han, L. et al. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer\/T-cell lymphoma. Oncol. Lett. 8, 1461\u20131469 (2014).","journal-title":"Oncol. Lett."},{"key":"BFnrclinonc2016168_CR141","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","volume":"34","author":"K Kantekure","year":"2012","unstructured":"Kantekure, K. et al. Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides. Am. J. Dermatopathol. 34, 126\u2013128 (2012).","journal-title":"Am. J. Dermatopathol."},{"key":"BFnrclinonc2016168_CR142","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/leu.2013.118","volume":"27","author":"S Munir","year":"2013","unstructured":"Munir, S. et al. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 27, 2251\u20132253 (2013).","journal-title":"Leukemia"},{"key":"BFnrclinonc2016168_CR143","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","volume":"128","author":"H Miyoshi","year":"2016","unstructured":"Miyoshi, H. et al. PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia\/lymphoma. Blood 128, 1374\u20131381 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR144","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1080\/10428190310001623694","volume":"44","author":"DG Maloney","year":"2003","unstructured":"Maloney, D. G. Graft-versus-lymphoma effect in various histologies of non-Hodgkin's lymphoma. Leuk. Lymphoma 44, S99\u2013S105 (2003).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2016168_CR145","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","volume":"22","author":"TS Fenske","year":"2016","unstructured":"Fenske, T. S. et al. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients. Biol. Blood Marrow Transplant. 22, 1543\u20131551 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrclinonc2016168_CR146","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bmt.2015.61","volume":"50","author":"S Pingali","year":"2015","unstructured":"Pingali, S. & Champlin, R. Pushing the envelope \u2014 nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 50, 1157\u20131167 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrclinonc2016168_CR147","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/bmt.2015.288","volume":"51","author":"X Chang","year":"2016","unstructured":"Chang, X., Zang, X. & Xia, C.-Q. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant. 51, 324\u2013332 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrclinonc2016168_CR148","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4049\/jimmunol.1402157","volume":"194","author":"R Deng","year":"2015","unstructured":"Deng, R. et al. B7H1\/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J. Immunol. 194, 560\u2013574 (2015).","journal-title":"J. Immunol."},{"key":"BFnrclinonc2016168_CR149","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","volume":"171","author":"BR Blazar","year":"2003","unstructured":"Blazar, B. R. et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-\u03b3-dependent mechanism. J. Immunol. 171, 1272\u20131277 (2003).","journal-title":"J. Immunol."},{"key":"BFnrclinonc2016168_CR150","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.4049\/jimmunol.162.11.6368","volume":"162","author":"BR Blazar","year":"1999","unstructured":"Blazar, B. R., Taylor, P. A., Panoskaltsis-Mortari, A., Sharpe, A. H. & Vallera, D. A. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 162, 6368\u20136377 (1999).","journal-title":"J. Immunol."},{"key":"BFnrclinonc2016168_CR151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.06.005","volume":"53","author":"N Okiyama","year":"2014","unstructured":"Okiyama, N. & Katz, S. I. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J. Autoimmun. 53, 1\u20139 (2014).","journal-title":"J. Autoimmun."},{"key":"BFnrclinonc2016168_CR152","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids, M. S. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375, 143\u2013153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR153","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.18632\/oncotarget.7593","volume":"7","author":"M Straub","year":"2016","unstructured":"Straub, M. et al. CD274\/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget 7, 12024\u201312034 (2016).","journal-title":"Oncotarget"},{"key":"BFnrclinonc2016168_CR154","doi-asserted-by":"crossref","first-page":"26483","DOI":"10.18632\/oncotarget.4494","volume":"6","author":"MT Barrett","year":"2015","unstructured":"Barrett, M. T. et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 6, 26483\u201326493 (2015).","journal-title":"Oncotarget"},{"key":"BFnrclinonc2016168_CR155","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/npjgenmed.2016.37","volume":"1","author":"S Ikeda","year":"2016","unstructured":"Ikeda, S. et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. Genomic Med. 1, 16037 (2016).","journal-title":"Genomic Med."},{"issue":"Suppl.","key":"BFnrclinonc2016168_CR156","first-page":"S1-09","volume":"75","author":"R Nanda","year":"2014","unstructured":"Nanda, R., Chow, L. & Dees, E. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 75 (Suppl.), abstr. S1-09 (2014).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2016168_CR157","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka, K. et al. Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature 534, 402\u2013406 (2016).","journal-title":"Nature"},{"key":"BFnrclinonc2016168_CR158","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrclinonc.2016.97","volume":"13","author":"D Killock","year":"2016","unstructured":"Killock, D. Immunotherapy: study deciphers enigmatic mechanism of PD-L1 overexpression. Nat. Rev. Clin. Oncol. 13, 395\u2013395 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc2016168_CR159","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","volume":"196","author":"AP Bally","year":"2016","unstructured":"Bally, A. P., Austin, J. W. & Boss, J. M. Genetic and epigenetic regulation of PD-1 expression. J. Immunol. 196, 2431\u20132437 (2016).","journal-title":"J. Immunol."},{"key":"BFnrclinonc2016168_CR160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2016168_CR161","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12185-015-1835-8","volume":"102","author":"N Nakamura","year":"2015","unstructured":"Nakamura, N. et al. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. Int. J. Hematol. 102, 327\u2013334 (2015).","journal-title":"Int. J. Hematol."},{"key":"BFnrclinonc2016168_CR162","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.1524668113","volume":"113","author":"W Ju","year":"2016","unstructured":"Ju, W. et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or navitoclax in a murine model of human Hodgkin's lymphoma. Proc. Natl Acad. Sci. USA 113, 1624\u20131629 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc2016168_CR163","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","volume":"112","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi, I. et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl Acad. Sci. USA 112, E966\u2013E972 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc2016168_CR164","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122, 2539\u20132549 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc2016168_CR165","first-page":"58","volume":"1865","author":"Y Xia","year":"2016","unstructured":"Xia, Y., Jeffrey Medeiros, L. & Young, K. H. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim. Biophys. Acta 1865, 58\u201371 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrclinonc2016168_CR166","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13073-015-0218-3","volume":"7","author":"MA Care","year":"2015","unstructured":"Care, M. A., Westhead, D. R. & Tooze, R. M. Gene expression meta-analysis reveals immune response convergence on the IFN\u03b3\u2013STAT1\u2013IRF1 axis and adaptive immune resistance mechanisms in lymphoma. Genome Med. 7, 96 (2015).","journal-title":"Genome Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2016.168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2016.168","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2016.168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T14:33:33Z","timestamp":1692542013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2016.168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,2]]},"references-count":166,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFnrclinonc2016168"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2016.168","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,2]]},"assertion":[{"value":"2 November 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. has received fellowship funding from Pfizer. S.P.P. has received research funding from Amgen, MedImmune, Pfizer, and Xcovery; consulting fees from Lilly; and speaking fees from Boehringer Ingelheim. R.K. has received research funds from Foundation Medicine, Genentech, Guardant, Merck Serono, Pfizer, and Sequenom; consultant fees from Sequenom; and has an ownership interest in CureMatch and Novena.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}